Autor(es):
Rosinha, Alina ; Rabaça, Carlos ; Calais, Fernando ; Pinto, João Moreira ; Barreira, João Vasco ; Fernandes, Ricardo ; Ramos, Rodrigo ; Fialho, Ana Cristina ; Palma dos Reis, José
Data: 2023
Identificador Persistente: http://hdl.handle.net/10400.14/44029
Origem: Veritati - Repositório Institucional da Universidade Católica Portuguesa
Assunto(s): High-risk; Identification; Non-metastatic castration-resistant prostate cancer; Prostate-specific antigen; Prostate-specific antigen doubling time; Standardization
Descrição
Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.
